Dabigatran/Verapamil
This information is generalized and not intended as specific medical advice. Consult your healthcare professional before taking or discontinuing any drug or commencing any course of treatment.
Medical warning:
Moderate. These medicines may cause some risk when taken together. Contact your healthcare professional (e.g. doctor or pharmacist) for more information.
How the interaction occurs:
When these two medicines are taken together, your body may not process dabigatran properly.
What might happen:
Your blood levels of dabigatran may increase, which could increase your risk for serious bleeding.
What you should do about this interaction:
Let your healthcare professionals (e.g. doctor or pharmacist) know that you are taking these medicines together. Your doctor may want to change or adjust the dose of your medication. Let your healthcare professional know if the side effects of your medicine increase.Your healthcare professionals may already be aware of this interaction and may be monitoring you for it. Do not start, stop or change the dosage of any medication before checking with them first.
References:
1.Pradaxa (dabigatran etexilate mesilate) UK summary of product characteristics. Boehringer Ingelheim Limited August 18, 2011.
2.Pradaxa (dabigatran etexilate mesylate) US prescribing information. Boehringer Ingelheim Pharmaceuticals, Inc. December, 2012.
3.Pradax (dabigatran etexilate mesilate) Canadian prescribing information. Boehringer Ingelheim June 13, 2011.
4.Anonymous. FDA Dabigatran background package for Cardio-Renal Advisory Committee. available at http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials /Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/UCM247244.pdf September 20, 2010.
